Current Report Filing (8-k)
November 18 2016 - 12:15PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(
d
)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
: November 18, 2016
Interpace Diagnostics Group
, Inc.
(Exact name of registrant as specified in its charter)
Delaware
|
|
000-24249
|
|
22-2919486
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
Morris Corporate Center 1, Building A
300 Interpace Parkway
Parsippany, NJ 07054
(Address, including zip code, of Principal Executive Offices)
(
855
)
776-6419
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 2
.0
2
.
Results of Operations and Financial Condition
.
On November 18, 2016, Interpace Diagnostics Group, Inc. issued a press release announcing its results of operations and financial condition for the quarter ended September 30, 2016. The full text of the press release is set forth as Exhibit 99.1 attached hereto and is incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise stated in such filing.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Exhibit Number
|
Description
|
99.1
|
Press Release dated November 18, 2016
|
signatureS
Pursuant to the requirements of the Securities Exchange
Act of
1934, the Registrant has duly caused
this report to be
signed on
its
behalf by
the undersigned hereunto duly authorized.
|
Interpace Diagnostics Group, Inc.
|
|
|
Date: November 18, 2016
|
By:
/s/ Jack E. Stover
Name: Jack E. Stover
Title: President and Chief Executive
Officer
|
EXHIBIT INDEX
Exhibit Number
|
Description
|
99.1
|
Press Release dated November 18, 2016
|
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Sep 2023 to Sep 2024